234 related articles for article (PubMed ID: 19902860)
1. Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article.
Bhattacharya S; Vijayasekar C; Worlding J; Mathew G
Acta Gastroenterol Belg; 2009; 72(3):289-95. PubMed ID: 19902860
[TBL] [Abstract][Full Text] [Related]
2. Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy.
Rosenoff SH
Eur J Cancer Care (Engl); 2004 Sep; 13(4):380-3. PubMed ID: 15305907
[TBL] [Abstract][Full Text] [Related]
3. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
Rosenoff S
Support Care Cancer; 2004 Aug; 12(8):561-70. PubMed ID: 15160318
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review.
Deng C; Deng B; Jia L; Tan H
BMJ Open; 2017 Jun; 7(6):e014916. PubMed ID: 28637728
[TBL] [Abstract][Full Text] [Related]
5. Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease.
Pai V; Porter K; Ranalli M
Pediatr Blood Cancer; 2011 Jan; 56(1):45-9. PubMed ID: 21108438
[TBL] [Abstract][Full Text] [Related]
6. Octreotide in the treatment of severe chemotherapy-induced diarrhea.
Zidan J; Haim N; Beny A; Stein M; Gez E; Kuten A
Ann Oncol; 2001 Feb; 12(2):227-9. PubMed ID: 11300329
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.
Rosenoff SH; Gabrail NY; Conklin R; Hohneker JA; Berg WJ; Warsi G; Maloney J; Benedetto JJ; Miles EA; Zhu W; Anthony L
J Support Oncol; 2006 Jun; 4(6):289-94. PubMed ID: 16805331
[TBL] [Abstract][Full Text] [Related]
8. Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Wadler S; Benson AB; Engelking C; Catalano R; Field M; Kornblau SM; Mitchell E; Rubin J; Trotta P; Vokes E
J Clin Oncol; 1998 Sep; 16(9):3169-78. PubMed ID: 9738589
[TBL] [Abstract][Full Text] [Related]
9. [Management of chemotherapy induced diarrhea].
Schultz M; Schölmerich J; Kullmann F
Z Gastroenterol; 2004 Jun; 42(6):527-38. PubMed ID: 15190449
[TBL] [Abstract][Full Text] [Related]
10. Role of octreotide in post chemotherapy and/or radiotherapy diarrhea: prophylaxis or therapy?
Sun JX; Yang N
Asia Pac J Clin Oncol; 2014 Jun; 10(2):e108-13. PubMed ID: 23297685
[TBL] [Abstract][Full Text] [Related]
11. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy.
Wasserman E; Hidalgo M; Hornedo J; Cortés-Funes H
Bone Marrow Transplant; 1997 Nov; 20(9):711-4. PubMed ID: 9384471
[TBL] [Abstract][Full Text] [Related]
12. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
Cascinu S; Fedeli A; Fedeli SL; Catalano G
J Clin Oncol; 1993 Jan; 11(1):148-51. PubMed ID: 8418225
[TBL] [Abstract][Full Text] [Related]
13. Systematic review: the use of somatostatin or octreotide in refractory diarrhoea.
Szilagyi A; Shrier I
Aliment Pharmacol Ther; 2001 Dec; 15(12):1889-97. PubMed ID: 11736719
[TBL] [Abstract][Full Text] [Related]
14. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
Topkan E; Karaoglu A
Oncology; 2006; 71(5-6):354-60. PubMed ID: 17873499
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.
Gebbia V; Carreca I; Testa A; Valenza R; Curto G; Cannata G; Borsellino N; Latteri MA; Cipolla C; Florena M
Anticancer Drugs; 1993 Aug; 4(4):443-5. PubMed ID: 8400346
[TBL] [Abstract][Full Text] [Related]
16. Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil.
Cascinu S; Fedeli A; Fedeli SL; Catalano G
Eur J Cancer; 1992; 28(2-3):482-3. PubMed ID: 1591068
[TBL] [Abstract][Full Text] [Related]
17. Octreotide in the management of treatment-related diarrhoea.
Baillie-Johnson HR
Anticancer Drugs; 1996 Jan; 7 Suppl 1():11-5. PubMed ID: 8822080
[TBL] [Abstract][Full Text] [Related]
18. Octreotide treatment of chemotherapy-induced diarrhoea.
Ginopoulos P; Papagiannis T; Safridi C; Karvelas F; Spyropoulos K; Papadas T; Gogos C
Eur J Cancer; 1996 Jan; 32A(1):182-3. PubMed ID: 8695236
[No Abstract] [Full Text] [Related]
19. Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.
Keefe DM; Elting LS; Nguyen HT; Grunberg SM; Aprile G; Bonaventura A; Selva-Nayagam S; Barsevick A; Koczwara B; Sonis ST
Cancer Chemother Pharmacol; 2014 Oct; 74(4):675-80. PubMed ID: 25055935
[TBL] [Abstract][Full Text] [Related]
20. Octreotide acetate in refractory bone marrow transplant-associated diarrhea.
Crouch MA; Restino MS; Cruz JM; Perry JJ; Hurd DD
Ann Pharmacother; 1996 Apr; 30(4):331-6. PubMed ID: 8729883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
